Soluble HER2 (sHER2) levels in HER2-positive breast cancer patients receiving chemotherapy ± trastuzumab: Results from the NCCTG adjuvant trial N9831

PURPOSE: IncreasedsHER2 is an indicator of poor prognosisin HER2+ metastatic breast cancer. This study evaluated the levels of sHER2 during treatment and at time of recurrence in the adjuvant N9831 clinical trial. PATIENTS AND METHODS: Aims were to describe sHER2 levels during treatment and at time...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Moreno-Aspitia, A., Hillman, D. W., Dyar, S. H., Tenner, K. S., Gralow, J., Kaufman, P. A., Davidson, N. E., Lafky, J. M., Reinholz, M. M., Lingle, W. L., Kutteh, L. A., Carney, W. P., Dueck, A. C., Perez, E. A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2013
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4126833/
https://ncbi.nlm.nih.gov/pubmed/23744760
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28130
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi